CD133+ endothelial progenitor cells as a potential cell source for a bioartificial glomerulus.
Development of a bioartificial glomerulus, a hemofilter in which the inner surface of hollow fibers is endothelialized, requires expandable, nonimmunogenic, antithrombogenic, and highly permeable endothelial cells. We used human umbilical cord blood CD133(+) endothelial progenitor cells (EPCs) to evaluate the feasibility of application of EPCs for bioartificial glomerulus. Numbers of adhered CD133(+) EPCs (adhered EPCs) was approximately 25 to 30 times as great in the expansion culture group as in the non-expansion group. Adhered EPCs had endothelial cell features, including the expression of CD31, Kinase domain region, von Willebrand factor, vascular endothelial-cadherin, positive for Ulex europeus agglutinin I staining, and up-take of acetylated low-density lipoprotein. Adhered EPCs secreted 6-keto-prostaglandin F(1alpha) identically to that secreted by human umbilical vein endothelial cells (HUVECs). The cells also expressed messenger RNA for phospholipase A(2), cyclooxygenase (COX)-1, COX-2, prostaglandin I(2) synthase, tissue plasminogen activator, and thrombomodulin (TM). TM protein in adhered EPCs properly activated protein C. Scanning electron microscopy revealed the suppression of platelet adhesion and aggregation on the surface of cell monolayer. Adhered EPCs treated with 50 microg/mL of cytochalasin B induced a larger diameter and a greater number of fenestrae, subsequently producing significantly more ultrafiltration than the non-treated cell. These results suggest that CD133(+) EPCs would potentially be applicable in bioartificial glomerulus.
Vu
Duc M
DM
Division of Nephrology and Metabolism, Department of Medicine, Tokai University School of Medicine, Kanagawa, Japan.
Masuda
Haruchika
H
Yokoyama
Tun A
TA
Fujimura
Satoshi
S
Kobori
Michiru
M
Ito
Rie
R
Sawada
Kaichiro
K
Saito
Akira
A
Asahara
Takayuki
T
D015121:6-Ketoprostaglandin F1 alpha / Q000378:metabolism; D000071916:AC133 Antigen; D015703:Antigens, CD / Q000378:metabolism*; D015820:Cadherins / Q000378:metabolism; D051545:Cyclooxygenase 1 / Q000235:genetics; D051546:Cyclooxygenase 2 / Q000235:genetics; D003571:Cytochalasin B / Q000494:pharmacology; D042783:Endothelial Cells / Q000166:cytology* / Q000187:drug effects / Q000378:metabolism; D005312:Fetal Blood / Q000166:cytology; D006023:Glycoproteins / Q000378:metabolism*; D006801:Humans; D007678:Kidney Glomerulus / Q000166:cytology* / Q000378:metabolism*; D008077:Lipoproteins, LDL / Q000378:metabolism; D010455:Peptides / Q000378:metabolism*; D037121:Plant Lectins / Q000378:metabolism; D019408:Platelet Endothelial Cell Adhesion Molecule-1 / Q000378:metabolism; D013234:Stem Cells / Q000166:cytology* / Q000187:drug effects / Q000378:metabolism*; D023822:Tissue Engineering / Q000379:methods*; D014471:Umbilical Veins / Q000166:cytology; D014841:von Willebrand Factor / Q000378:metabolism; D000099152:Cadherin 5
D015121:6-Ketoprostaglandin F1 alpha; D000071916:AC133 Antigen; D015703:Antigens, CD; D015820:Cadherins; D051545:Cyclooxygenase 1; D051546:Cyclooxygenase 2; D003571:Cytochalasin B; D006023:Glycoproteins; D008077:Lipoproteins, LDL; D010455:Peptides; D037121:Plant Lectins; D019408:Platelet Endothelial Cell Adhesion Molecule-1; D014841:von Willebrand Factor; D000099152:Cadherin 5; C000606023:PROM1 protein, human; C036850:Ulex europaeus lectins